Envestnet Boosts Stake in Merck & Co., Inc. by 28.3% Amid Pipeline Progress

Envestnet Portfolio Solutions Inc., a financial services company, has increased its stake in Merck & Co., Inc. (NYSE:MRK) by 28.3% during the second quarter. According to its most recent disclosure with the Securities & Exchange Commission, Envestnet acquired an additional 23,240 shares of MRK's stock. This brings their total holdings in MRK to 105,500 shares, valued at $13.56 million as of the company's latest SEC filing.

This is not the only instance of increased investment in Merck & Co., Inc. during the second quarter. Several other large investors have also boosted their stakes in the company, including Hager Investment Management Services LLC, Physician Wealth Advisors Inc., Motive Wealth Advisors, and Sound Income Strategies LLC. These investors collectively own approximately 76% of MRK's stock.

Despite these investments, some analysts are cautioning about potential risks to Merck & Co.'s growth. Keytruda, the company's largest growth driver, is facing patent expiration and increasing competition, which could pressure its sales in the future. However, other analysts remain optimistic about MRK's pipeline progress and business-development activity.